Vancouver, BC (March 04,2017) – Virogin Biotech Ltd. (“Virogin”) is pleased to announce the completion of its Series A+ round of financing for a total of$5 million USD on February 28th, 2017. Virogin Biotech Ltd. specializes in cancer therapeutics research and discovery with a strong focus on innovative oncolytic virotherapy. The financing was led by … Continue reading “Virogin Biotech Ltd. Announces $5 Million in Series A+ Financing”
Vancouver, BC (August 18, 2016) – Virogin Biotech Ltd. (“Virogin”) is pleased to announce its strategic collaboration with Guangdong University of Technology (GDUT) in China.
Vancouver, BC – ViroGin Biotech Canada Ltd. (“ViroGin”) is pleased to announce that it has received approval for NRC-IRAP funding on April 22, 2016. ViroGin Biotech Canada Ltd. specializes in anti-cancer drug research with a focus on oncolytic virology. The National Research Council-Industrial Research Assistance Program (NRC-IRAP) is Canada’s premier innovation assistance program for small … Continue reading “ViroGin Biotech Canada Ltd. Approved for NRC-IRAP Funding”
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to professionals working in the field of cancer immunology and immunotherapy. Established in 1984, SITC is a 501(c)(3) not-for-profit organization with a growing constituency of more than 1,000 academic, government, industry, clinical and basic scientists and medical profession -als from … Continue reading “SITC: Immunotherapy Today!”
British Columbia’s Life Sciences Community always has good reason to celebrate. Whether it is the excellent basic research leading to translation or the pre-clinical work that gives way to clinical research and over 799 active clinical trials in the Province or the energetic entrepreneurs that start and grow companies with the support of advisors, institutions … Continue reading “17th Annual LifeSciences BC Awards, presented by FARRIS – C”
ViroGin Biotech Announces Collaboration with Johnson & Johnson Innovation to Further Development of Oncolytic Therapeutics ViroGin Biotech Ltd (ViroGin), an early stage biotech research company, today announced a collaboration agreement with Johnson & Johnson Innovation and Janssen Biotech, Inc. (“Janssen”) to further the development of ViroGin’s novel oncolytic therapeutics for the treatment of cancer. … Continue reading “ViroGin Biotech Announces Collaboration with Johnson & Johnson”